AASLD Practice Guideline

You have full text access to this OnlineOpen article

Management of hepatocellular carcinoma: An update †‡

  1. Jordi Bruix1,§,*,
  2. Morris Sherman2

Article first published online: 2 MAR 2011

DOI: 10.1002/hep.24199

Issue

Hepatology

Hepatology

Volume 53, Issue 3, pages 1020–1022, March 2011

Additional Information

How to Cite

Bruix, J. and Sherman, M. (2011), Management of hepatocellular carcinoma: An update . Hepatology, 53: 1020–1022. doi: 10.1002/hep.24199

Author Information

  1. 1

    Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

  2. 2

    University of Toronto and University Health Network, Toronto, Canada

  1. §

    fax: (34) 93-227-9803

*Hospital Clinic, University of Barcelona, IDIPAPS, CIBERehd, c/Villarroel 170, Barcelona 08036, Catalonia, Spain

  1. †

    Potential conflict of interest: Dr. Bruix advises, consults for, serves on the speaker's bureau of, and received grants from Bayer. Dr. Bruix consults for Biocompatibles, GlaxoSmithKline, Kowa, Novartis, and Arqule. Dr. Bruix also advises and consults for Bristol-Myers Squibb. Dr. Sherman serves on the speakers' bureau of Bayer

  2. ‡

    Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms

  3. §

    fax: (34) 93-227-9803

Publication History

  1. Issue published online: 2 MAR 2011
  2. Article first published online: 2 MAR 2011
  3. Accepted manuscript online: 19 JAN 2011 09:02AM EST
  4. Manuscript Accepted: 8 JAN 2011
  5. Manuscript Received: 3 JAN 2011

Funded by

  • Unknown funding agency

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (217K)

References

  • 1
    Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-88.
  • 2
    Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010; 28: 2437-2444.
  • 3
    Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-148.
  • 4
    Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. HEPATOLOGY 2008; 48: 863-870.
    Direct Link:
  • 5
    Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
    Direct Link:
  • 6
    Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. ; HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
  • 7
    Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. HEPATOLOGY 2008; 47: 97-104.
    Direct Link:
  • 8
    Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59: 638-644.
  • 9
    Khalili K, Kim TY, Jang HJ, Haider MA, Guindi M, Sherman M. Implementation of AASLD hepatocellular carcinoma practice guidelines in North America: two years of experience [Abstract]. HEPATOLOGY 2008; 48( Suppl 1): 362A.
  • 10
    International Working Party. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. HEPATOLOGY 2009; 49: 658-664.
    Direct Link:
  • 11
    Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
  • 12
    Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916.
  • 13
    Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? HEPATOLOGY 2008; 47: 82-89.
    Direct Link:
  • 14
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
  • 15
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
View Full Article (HTML) Get PDF (217K)